Tuesday, November 4, 2014

Zenosense, Inc. (ZENO) Pre-Commercial Lung Cancer Detection Device Manufacturing Underway

Zenosense, a healthcare technology company principally engaged in developing and marketing devices to detect the MRSA “Super-Bug” and to detect signs of lung cancer in exhaled breath, announced it has manufactured a pre-commercial prototype device. The device is expected to be evaluated for the detection of lung cancer in exhaled breath.

The work involved in the prototyping process has been entrusted to the company’s contracted development partner Zenon Biosystem (“Zenon”), a component of the Sgenia group. In line with the protocol design for an anticipated lung cancer detection trial, two pre-commercial devices are currently being manufactured with the identical design, thereby ensuring the results are reproduced. The devices are expected to be ready later this month.

The device uses components that remove irrelevant Volatile Organic Compounds (“VOCs”) in order to optimize the detection of target VOC biomarkers found in exhaled breath and connected with the incidence of lung cancer. These components include molecular sieves used in complementary layered and mixed sensor structures to screen incoming VOCs, and nanometric sensing mesh to maximize the detective area.

ZENO is eagerly anticipates testing of the devices in the planned lung cancer detection trial while work at Zenon is ongoing to establish the necessary outcomes to carry out the trial. The company believes that a cost-effective lung cancer detector analyzing exhaled breath proven meets or exceeds the accuracy of low dose CT scanning will have wide appeal and subsequently satisfy demand.

Zenosense, Inc., a detection device development company, outlays a mission to develop effective medical devices targeting early detection of both deadly bacteria and certain cancers in the exhaled breath of patients. Ultimately, the company intends to sell these products to primary healthcare facilities and hospitals. A device intended to detect the Methicillin-resistant Staphylococcus aureus MRSA and a device intended to detect Lung Cancer are currently under development.

For more information on the company, visit www.zenosense.net

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

No comments: